MedTrace Logo

Predictive Value of Maternal Blood Protein Signatures in Preterm Birth

NCT06664554 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18000

Last updated 2024-12-05

No results posted yet for this study

Summary

Accurate prediction of preterm birth is critical for clinical management to improve the neonatal and maternal outcomes. A clinical challenge remains for current predicting biomarkers due to the complexity and multifactorial nature of underlying causes of preterm birth.

This study aims to evaluate the prediction performance of new maternal blood biomarkers (proteomic markers) on the occurrence of preterm birth.

Conditions

Sponsors & Collaborators

  • Shenzhen Maternity & Child Healthcare Hospital

    collaborator OTHER

  • HBI Solutions Inc.

    lead INDUSTRY

Principal Investigators

  • Qiong Luo, M.D. Ph.D. · Department of Obstetrics, Women's Hospital of Zhejiang University, School of Medicine, Hangzhou, 310006, China

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06664554 on ClinicalTrials.gov